UNSPSC 85444504: The diagnosis of macrolides

In this classification, this covers the group of activities that yields a diagnosis of macrolides. Macrolides is listed In The World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10) as a four-character category under code Y40.3.

UNSPSC 85444504 Diagnosis of macrolides, a Commodity code, nominally addresses antibiotic testing and identification, but recent state and local procurement activity under this code shows misalignment with the code's abstract scope. The three most recent opportunities posted across the code involve diagnostic imaging infrastructure (a PACS system), ultrasound equipment procurement, and phlebotomy services—none of which involve macrolide diagnosis or antibiotic susceptibility testing. San Mateo Medical Center posted an RFP for enterprise-grade Picture Archiving and Communication System implementation with EPIC Electronic Health Record integration, Collier County Florida issued a Notice of Intent to single-source KOSMOS ultrasound equipment from EchoNous Inc., and the Albuquerque Police Department posted an RFB for on-call blood draw services. The issuing bodies span a county public health system (San Mateo), a county procurement office (Collier), and a municipal police department (Albuquerque). State and local buyers are tagging general diagnostic and clinical support services under this code despite the nominal macrolide-specific scope.

Geographic activity appears concentrated in California and Florida, with additional activity in New Mexico. The San Mateo Medical Center PACS opportunity closes August 7, 2026, and requires comprehensive imaging infrastructure covering radiology, cardiology, and dental imaging with 99.9% uptime and EPIC integration; evaluation emphasizes project approach (30 points), firm qualifications (25 points), team qualifications (20 points), and price (25 points), with a 5-10% local preference available under county ordinance. The mismatch between the code's nominal macrolide-diagnosis scope and the actual diagnostic equipment and clinical service procurements being tagged suggests either systematic miscoding by issuing bodies or a broader code definition in use than the taxonomy name reflects. Firms pursuing opportunities under this code should expect diagnostic imaging systems, medical equipment, and clinical laboratory support services rather than pharmaceutical or antibiotic-focused work.